Skip to main content
Log in

Attributable causes of breast cancer and ovarian cancer in China: Reproductive factors, oral contraceptives and hormone replacement therapy

  • Original Article
  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

To provide an evidence-based, consistent assessment of the burden of breast cancer attributable to reproductive factors (RFs, including nulliparity, mean number of children, age at first birth and breastfeeding), use of oral contraceptives (OCs, restricted to the age group of 15–49 years), and hormone replacement therapy (HRT), as well as of the burden of ovarian cancer attributable to the mean number of children in China in 2005.

Methods

We derived the prevalence of these risk factors and the relative risk of breast and ovarian cancer from national surveys or large-scale studies conducted in China. In the case of RFs, we compared the exposure distributions in 2001 and counterfactual exposure.

Results

Exposure of RFs in 2001 was found to account for 6.74% of breast cancer, corresponding to 9,617 cases and 2,769 deaths, and for 2.78% of ovarian cancer (711 cases, 294 deaths). The decrease in mean number of children alone was responsible for 1.47% of breast cancer and 2.78% of ovarian cancer. The prevalence of OC use was 1.74% and the population attributable fraction (PAF) of breast cancer was 0.71%, corresponding to 310 cases and 90 deaths. The PAF of breast cancer due to HRT was 0.31%, resulting in 297 cases and 85 deaths.

Conclusion

RFs changes in China contributed to a sizable fraction of breast and ovarian cancer incidence and mortality, whereas HRT and OCs accounted for relatively low incidence of breast cancer in China.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893–2917.

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006; 12(Suppl 1):S70–S80.

    Article  PubMed  Google Scholar 

  3. Pathak DR, Osuch JR, He J. Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 2000; 88(5 Suppl):1230–1238.

    Article  PubMed  CAS  Google Scholar 

  4. Pike MC, Krailo MD, Henderson BE, et al. ’Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 1983; 303:767–770.

    Article  PubMed  CAS  Google Scholar 

  5. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15:17–35.

    PubMed  CAS  Google Scholar 

  6. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15:36–47.

    PubMed  CAS  Google Scholar 

  7. Salehi F, Dunfield L, Phillips KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008; 11:301–321.

    Article  PubMed  CAS  Google Scholar 

  8. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472:413–437.

    Article  PubMed  Google Scholar 

  9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2007; 91:1–528.

    Google Scholar 

  10. Madigan MP, Ziegler RG, Benichou J, et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995; 87:1681–1685.

    Article  PubMed  CAS  Google Scholar 

  11. International Agency for Research on Cancer, Académie des Sciences—Institut de France, Académie de Médecine, Fédération Nationale des Centres de Lutte contre le Cancer. IARC Working Group Reports, Vol. 3. Attributable Causes of Cancer in France in the Year 2000. Lyon (France): IARC Press; 2007.

    Google Scholar 

  12. Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6:552–553.

    Article  PubMed  Google Scholar 

  13. Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer 2008; 44:2344–2349.

    Article  PubMed  CAS  Google Scholar 

  14. Ministry of Health of P.R. China. Year Book of Health in the People’s Republic of China. Beijing: People’s Health Press; 2004.

    Google Scholar 

  15. National Family Planning Commission of P.R. China. Year Book of Population and Family Planning in the People’s Republic of China. Beijing: China Population Press; 2004.

    Google Scholar 

  16. National Family Planning Commission of P.R. China. Year Book of Family Planning in the People’s Republic of China. Beijing: China Population Press; 1990.

    Google Scholar 

  17. National Family Planning Commission of P. R. China. Year Book of Population and Family Planning in the People’s Republic of China. Beijing: China Population Press; 2003.

    Google Scholar 

  18. Department of Population and Social Technology Statistics, National Bureau of Statistics. 97 China Population. Beijing: China Statistics Press; 1998.

    Google Scholar 

  19. National Family Planning Commission of P.R. China. Year Book of Population and Family Planning in the People’s Republic of China. Beijing: China Population Press; 2008.

    Google Scholar 

  20. National Family Planning Commission of P.R. China. Year Book of Population and Family Planning in the People’s Republic of China. Beijing: China Population Press; 2005.

    Google Scholar 

  21. Statistical Information Center, Ministry of Health of P.R. China. Abstract of the report on the 3rd National Health Service Investigation and Analysis: Investigation and Research on China Health Service. Beijing: Peking Union Medical College Press; 2004.

    Google Scholar 

  22. Liang JM, Chen SL. Statistics of 1988 National Fertility and Contraceptive sampling survey: the 3rd part: fertility and contraceptive. Beijing: China Population Press; 1992.

    Google Scholar 

  23. Jiang ZH, Zhang EL, Chen SL, et al. Statistics of 1992 fertility sampling survey in China. Beijing: China Population Press; 1996.

    Google Scholar 

  24. Jiang ZH. Data collection of 1997 national population and reproductive health survey. Beijing: China Population Press; 2000.

    Google Scholar 

  25. Liang JM, Chen SL. Statistics of 1988 National Fertility and Contraceptive sampling survey: the 1st part: Population Structure. Beijing: China Population Press; 1992.

    Google Scholar 

  26. Department of Population Statistics, National Bureau of Statistics. Statistics of 1987 one-per-hundredth population sampling survey in China: National Data. Beijing: China Statistics Press; 1988.

    Google Scholar 

  27. Department of Population Statistics, National Bureau of Statistics. National Report of 1985 phase I intensive fertility survey in China: part I. Beijing: China Statistics Press; 1986.

    Google Scholar 

  28. Department of Population Statistics, National Bureau of Statistics. Statistics of 1995 one-per-hundredth population sampling survey in China. Beijing: China Statistics Press; 1996.

    Google Scholar 

  29. National Family Planning Commission of P. R. China. Statistics of 1988 National Fertility and Contraceptive sampling survey-National Data (Six Volumes): Volume I, Summed Data. Beijing: China Population Press; 1989.

    Google Scholar 

  30. Pan GY, Zhang HX, Wang Q, et al. Statistics of 2001 National Family Planning and Reproductive Health sampling survey. Beijing: China Population Press; 2004.

    Google Scholar 

  31. Research Institute of All China Women’s Federation Research Office of Shanxi Provincial Women’s Federation. Statistics on Chinese women, 1949–1989. Beijing: China Statistics Press; 1991.

    Google Scholar 

  32. Yao XW. Fertility data of China. Beijing: China Population Press; 1995.

    Google Scholar 

  33. Wu C, Ray RM, Lin MG, et al. A case-control study of risk factors for fibrocystic breast conditions: Shanghai Nutrition and Breast Disease Study, China, 1995–2000. Am J Epidemiol 2004; 160:945–960.

    Article  PubMed  Google Scholar 

  34. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000; 87:295–300.

    Article  PubMed  CAS  Google Scholar 

  35. Chen Y, Wu PC, Lang JH, et al. Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992; 21:23–29.

    Article  PubMed  CAS  Google Scholar 

  36. Pei GJ, Fu L, Cui YL, et al. Meta-analysis of risk factors of breast cancer in Chinese women. Zhong Guo Fu You Bao Jian (in Chinese) 2008; 23:2650–2652.

    Google Scholar 

  37. Zhang JB, Feng XX. Meta-analysis on risk factors of breast cancer. Zhong Guo Wei Sheng Tong Ji (in Chinese) 2002; 19:168–170.

    Google Scholar 

  38. Xiao YH, Yan ZH, Zhang WJ, et al. Meta-analysis of Chinese literatures on oral contraceptives and breast cancer. Yao Wu Liu Xing Bing Xue Za Zhi (in Chinese) 2000; 9:179–181.

    Google Scholar 

  39. Han YF, Wu B, Wang JQ. Meta-analysis of relationship between oral contraceptives and breast cancer. Qi Qi Ha Er Yi Xue Yuan Xue Bao (in Chinese) 2006; 27:703–704.

    Google Scholar 

  40. Huang W, Peng W, Wu YQ, et al. The status quo of perimenopausal and postmenopausal women in Chengdu: report of a population-based cross-sectional study. Si Chuan Da Xue Xue Bao (Yi Xue Ban) (in Chinese) 2003; 34:536–538.

    Google Scholar 

  41. Chen CX. A trial for perimenopause and postmenopause women in Chongzhou: a population-based across-sectional study. Hua Xi Yi Xue (in Chinese) 2003; 18:168–169.

    Google Scholar 

  42. Zhang SW, Wang JH, Zhou H, et al. The investigation and analysis of the hormone replacement therapy of perimenopausal women in Beijing. Zhong Guo Fu You Bao Jian (in Chinese) 2004; 19:45–46.

    CAS  Google Scholar 

  43. Tian FL, Yang DZ, Zhang XZ, et al. Survey of health status and healthcare service demand of perimenopausal women in Guangdong. Di Yi Jun Yi Da Xue Xue Bao (in Chinese) 2004; 24:928–932.

    Google Scholar 

  44. Zhao XX, Yuan L, Xiu XH, et al. A survey of healthcare service demand of perimenopausal women in Qingdao. Zhong Guo Zi Ran Yi Xue Za Zhi (in Chinese) 2007; 9:396–399.

    Google Scholar 

  45. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419–427.

    Article  PubMed  CAS  Google Scholar 

  46. Chen WQ. Estimation of cancer incidence and mortality in China in 2004–2005. Zhong Hua Zhong Liu Za Zhi (in Chinese) 2009; 31:664–668.

    Google Scholar 

  47. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953; 9:531–541.

    PubMed  CAS  Google Scholar 

  48. Spicer DV, Pike MC. Epidemiology of breast cancer. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press; 1994.

    Google Scholar 

  49. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713–1727.

    Article  Google Scholar 

  50. Rosenberg L, Palmer JR, Rao SR, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996; 143:25–37.

    PubMed  CAS  Google Scholar 

  51. Connelly MT, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990–1995. J Gen Intern Med 2000; 15:542–550.

    Article  PubMed  CAS  Google Scholar 

  52. Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45–65 years: prevalence, determinants, and compliance. Obstet Gynecol 1997; 90:269–277.

    Article  PubMed  CAS  Google Scholar 

  53. Moorhead T, Hannaford P, Warskyi M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol 1997; 104:290–297.

    Article  PubMed  CAS  Google Scholar 

  54. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002; 7:3–15.

    Article  PubMed  Google Scholar 

  55. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348:2339–2347.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to You-lin Qiao or Paolo Boffetta.

Additional information

This work was supported by International Agency for Research on Cancer (Lyon, France) (No. CRA No GEE/08/19), and supported in part by the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988).

Contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, L., Ji, J., Wang, Jb. et al. Attributable causes of breast cancer and ovarian cancer in China: Reproductive factors, oral contraceptives and hormone replacement therapy. Chin. J. Cancer Res. 24, 9–17 (2012). https://doi.org/10.1007/s11670-012-0009-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-012-0009-y

Key words

Navigation